Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Annovis Bio has commenced the treatment of subjects in a Phase III clinical trial of buntanetap in treating early Alzheimer's ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

Chicago Partners Investment Group LLC decreased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 35.7% during the 4th quarter, Holdings Channel.com reports. The ...

In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has updated employment agreements with key executive officers, including ...

Researchers have devised a revolutionary, noninvasive method to monitor blood glucose, allowing for accurate measurements of ...

Shanghai researchers have devised a revolutionary, non-invasive method to monitor blood glucose, allowing for accurate blood ...